ClinicalTrials.gg
CompletedNCT01746745Updated Jul 22, 2019Results posted

A Study of LY2940680 in Healthy Participants

A Phase 1 interventional study of [^14C]-LY2940680 in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-07-22.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This is a single dose study of radiolabelled LY2940680 taken by mouth in healthy participants to study how the body absorbs and removes LY2940680 from the blood. This study is for research purposes only and is not intended to treat any medical condition.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Generally healthy sterile males or surgically sterile females or females, as determined by medical history and laboratory assessments
  • Have a (BMI) of 18.5 to 32.0 kilograms per square meter (kg/m\^2), inclusive

Exclusion criteria

Exclusion Criteria:

  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Have consumed herbal supplements, grapefruit juice, grapefruits, grapefruit containing products, Seville orange juice, Seville oranges, star fruit, or star fruit juice within 7 days prior to dosing or intend to consume during the study
  • Have donated blood of more than 500 milliliters (mL) within the last month
  • Have participated in a [\^14C]-study within the last 6 months prior to admission for this study
  • Exposure to significant radiation within 12 months prior to dose (for example, serial X-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • Have a pattern less than once per 2 days to expel feces from the bowel through the rectum or acute constipation within 3 weeks of the day prior to dose
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    [^14C]-LY2940680

    Single 100 milligram (mg) dose of LY2940680 containing 100 microCuries of carbon-14-labeled LY2940680 (\[\^14C\]-LY2940680)

    Drug: [^14C]-LY2940680

Interventions

06

What researchers measure

Primary outcomes

  1. Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    The percentage of the total radioactive dose administered that was excreted in feces = \[(amount of radioactivity recovered in feces)/(radioactive dose administered)\]\*100.

    Time frame: Predose up to 14 days postdose. Samples collected at 24-h intervals.

  2. Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    The percentage of the total radioactive dose administered that was excreted in urine=\[(amount of radioactivity recovered in urine)/(radioactive dose administered)\]\*100.

    Time frame: Predose up to 14 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.

Secondary outcomes

  1. Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)

    The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.

    Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter

  2. PK of Radioactivity: Cmax

    Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.

  3. PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)

    The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.

    Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.

  4. Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]

    Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.

  5. PK of Radioactivity: AUC(0 to Tlast)

    AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms\*hour equivalents per gram (ng\*h Eq/g).

    Time frame: Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.

  6. Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma

    Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=\[(radioactivity in peak)/(radioactivity in sample)\]\*100. Metabolites with a relative abundance ≤6% are not reported.

    Time frame: Day 1 up to 3 days postdose. Samples collected at 2, 3, 4, 6, and 8 h postdose on Day 1 and every 24 h thereafter.

  7. Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine

    Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.

    Time frame: Predose up to 4 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.

  8. Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces

    Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.

    Time frame: Predose up to 8 days postdose. Samples collected at 24-h intervals.

07

Results

Posted Jul 22, 2019

Participant flow

Participant flow — Overall Study
Milestone[^14C]-LY2940680
Started6
Received study drug6
Completed6
Not completed0

Outcome measures

PrimaryFecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

The percentage of the total radioactive dose administered that was excreted in feces = \[(amount of radioactivity recovered in feces)/(radioactive dose administered)\]\*100.

Time frame:
Predose up to 14 days postdose. Samples collected at 24-h intervals.
Reported as:
Mean · percentage of dose administered
Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
percentage of dose administered[^14C]-LY2940680
Fecal Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered82.7 ± 2.81
PrimaryUrinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

The percentage of the total radioactive dose administered that was excreted in urine=\[(amount of radioactivity recovered in urine)/(radioactive dose administered)\]\*100.

Time frame:
Predose up to 14 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.
Reported as:
Mean · percentage of dose administered
Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
percentage of dose administered[^14C]-LY2940680
Urinary Excretion of LY2940680 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered14.6 ± 1.68
SecondaryPlasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)

The Cmax of LY2940680 and its equipotent active metabolite in the free base form, LSN3185556, is reported.

Time frame:
Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Plasma PK of LY2940680 and LSN3185556: Maximum Observed Concentration (Cmax)
nanograms per milliliter (ng/mL)[^14C]-LY2940680
Plasma LY2940680831 ± 6
Plasma LSN31855561210 ± 25
SecondaryPK of Radioactivity: Cmax
Time frame:
Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Reported as:
Geometric mean · nanogram equivalents per gram (ng Eq/g)
PK of Radioactivity: Cmax
nanogram equivalents per gram (ng Eq/g)[^14C]-LY2940680
Plasma Total Radioactivity2380 ± 7
Whole Blood Total Radioactivity1520 ± 6
SecondaryPK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)

The Tmax of LY2940680, LSN3185556, and total radioactivity in plasma are reported, as well as the Tmax for total radioactivity in whole blood.

Time frame:
Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Reported as:
Median · h
PK of LY2940680, LSN3185556, and Radioactivity: Time of Maximum Observed Concentration (Tmax)
h[^14C]-LY2940680
Plasma LY29406801.51 (1.00 to 3.00)
Plasma LSN31855562.50 (2.00 to 4.02)
Plasma Total Radioactivity2.00 (1.00 to 3.00)
Whole Blood Total Radioactivity2.00 (1.00 to 3.00)
SecondaryPlasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]
Time frame:
Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*h/mL)
Plasma PK of LY2940680 and LSN3185556: Area Under the Concentration-Time Curve From Time 0 to the Last Time Point With a Measurable Concentration [AUC(0 to Tlast)]
nanograms*hour per milliliter (ng*h/mL)[^14C]-LY2940680
Plasma LY29406805680 ± 19
Plasma LSN318555620400 ± 32
SecondaryPK of Radioactivity: AUC(0 to Tlast)

AUC(0 to Tlast) of total radioactivity in plasma and whole blood are reported in nanograms\*hour equivalents per gram (ng\*h Eq/g).

Time frame:
Predose up to 14 days postdose. Samples collected at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 h postdose on Day 1 and every 24 h thereafter.
Reported as:
Geometric mean · ng*h Eq/g
PK of Radioactivity: AUC(0 to Tlast)
ng*h Eq/g[^14C]-LY2940680
Plasma Total Radioactivity64800 ± 16
Whole Blood Total Radioactivity38200 ± 18
SecondaryRelative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma

Relative abundance was expressed and calculated as the percentage of plasma sample radioactivity=\[(radioactivity in peak)/(radioactivity in sample)\]\*100. Metabolites with a relative abundance ≤6% are not reported.

Time frame:
Day 1 up to 3 days postdose. Samples collected at 2, 3, 4, 6, and 8 h postdose on Day 1 and every 24 h thereafter.
Reported as:
Mean · percentage of sample radioactivity
Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Plasma
percentage of sample radioactivity[^14C]-LY2940680
LY2940680 (parent)11.1 ± 2.54
Metabolite M75 (LSN3185556)52.0 ± 5.14
Metabolite M6317.1 ± 1.71
SecondaryRelative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine

Relative abundance was expressed and calculated as the percentage of administered dose excreted in urine=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.

Time frame:
Predose up to 4 days postdose. Samples collected at 6-h intervals on Day 1 (0-6, 6-12, and 12-24 h postdose) and at 24-h intervals thereafter.
Reported as:
Mean · percentage of administered dose excreted
Relative Abundance of LY2940680 and the Metabolites of LY2940680 in Urine
percentage of administered dose excreted[^14C]-LY2940680
LY2940680 (parent)0.105 ± 0.0937
Metabolite M432.87 ± 0.816
Metabolite M631.82 ± 0.740
SecondaryRelative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces

Relative abundance was expressed and calculated as the percentage of the administered dose excreted in feces=\[(percentage of radioactivity in peak)/100\]\*(percentage of dose in sample). Metabolites with a relative abundance ≤1% are not reported.

Time frame:
Predose up to 8 days postdose. Samples collected at 24-h intervals.
Reported as:
Mean · percentage of administered dose excreted
Relative Abundance of LY2940680, the Metabolites of LY2940680, and LSN3185556 in Feces
percentage of administered dose excreted[^14C]-LY2940680
LY2940680 (parent)0.431 ± 0.313
Metabolite M4337.1 ± 1.65
Metabolite M493.04 ± 0.861
Metabolite M733.19 ± 1.43
LSN31855562.90 ± 1.09

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
[^14C]-LY2940680—0/6 (0%)3/6 (50%)
Most frequent other events
Most frequent other events
Event[^14C]-LY2940680
DiarrhoeaGastrointestinal disorders2/6
Abdominal distensionGastrointestinal disorders1/6
Soft tissue massMusculoskeletal and connective tissue disorders1/6
HeadacheNervous system disorders1/6

Baseline characteristics

Enrolled participants who received study drug and had at least 1 safety assessment postdose.

Age, Customized
Age, Customized(Participants)[^14C]-LY2940680
44 to 59 years6
Sex: Female, Male
Sex: Female, Male(Participants)[^14C]-LY2940680
Female6
Male0
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)[^14C]-LY2940680
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)[^14C]-LY2940680
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)[^14C]-LY2940680
United States6
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Madison, Wisconsin 53704, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2013, a primary completion of Mar 2013 and a completion of Mar 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2019, 6 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 7, 2012
First posted
Dec 11, 2012
Start
Jan 2013
Primary completionActual
Mar 2013
CompletionActual
Mar 2013
Results first posted
Jul 22, 2019
Last update
Jul 22, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01746745
Responsible party
Sponsor
First posted
Dec 11, 2012
Start date
Jan 2013
Primary completion
Mar 2013
Completion
Mar 2013
Results posted
Jul 22, 2019
Last update
Jul 22, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LY2940680

Start the discussion